TetraLogic Pharmaceuticals Corporation
TetraLogic Pharmaceuticals Corporation
Your view on TLOG
Overview
What the company does, where it operates, and who runs it.
About TetraLogic Pharmaceuticals Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Yigong Shi
- Headquarters
- 343 Phoenixville Pike, Malvern, PA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Yigong Shi
- Headquarters
- 343 Phoenixville Pike, Malvern, PA, US
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE.
Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma.
TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006.
TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for TetraLogic Pharmaceuticals Corporation, and the rating behind it. TLOG last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for TetraLogic Pharmaceuticals Corporation. Starting points for TetraLogic Pharmaceuticals Corporation: EPS -$2.37, beta 4.06 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for TetraLogic Pharmaceuticals Corporation. TetraLogic Pharmaceuticals Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for TetraLogic Pharmaceuticals Corporation. Trailing twelve-month EPS for TetraLogic Pharmaceuticals Corporation stands at -$2.37. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for TetraLogic Pharmaceuticals Corporation. TetraLogic Pharmaceuticals Corporation has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
TetraLogic Pharmaceuticals Corporation valued side by side against its closest peers. TetraLogic Pharmaceuticals Corporation is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold TetraLogic Pharmaceuticals Corporation, and how their positions are changing. At a $2,447 market value, institutional positions materially move TetraLogic Pharmaceuticals Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by TetraLogic Pharmaceuticals Corporation executives and directors. Shares of TetraLogic Pharmaceuticals Corporation have traded between $0.0001 and $0.0010 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming TetraLogic Pharmaceuticals Corporation. TetraLogic Pharmaceuticals Corporation is a $2,447 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming TetraLogic Pharmaceuticals Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for TetraLogic Pharmaceuticals Corporation. Coverage tracks TetraLogic Pharmaceuticals Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.